Abstract

Among the several new antimalarials discovered over the past decade are at least three clinical candidate drugs, each with a distinct chemical structure, that disrupt Na+ homeostasis resulting in a rapid increase in intracellular Na+ concentration ([Na+]i) within the erythrocytic stages of Plasmodium falciparum. At present, events triggered by Na+ influx that result in parasite demise are not well-understood. Here we report effects of two such drugs, a pyrazoleamide and a spiroindolone, on intraerythrocytic P. falciparum. Within minutes following the exposure to these drugs, the trophozoite stage parasite, which normally contains little cholesterol, was made permeant by cholesterol-dependent detergents, suggesting it acquired a substantial amount of the lipid. Consistently, the merozoite surface protein 1 and 2 (MSP1 and MSP2), glycosylphosphotidylinositol (GPI)-anchored proteins normally uniformly distributed in the parasite plasma membrane, coalesced into clusters. These alterations were not observed following drug treatment of P. falciparum parasites adapted to grow in a low [Na+] growth medium. Both cholesterol acquisition and MSP1 coalescence were reversible upon the removal of the drugs, implicating an active process of cholesterol exclusion from trophozoites that we hypothesize is inhibited by high [Na+]i. Electron microscopy of drug-treated trophozoites revealed substantial morphological changes normally seen at the later schizont stage including the appearance of partial inner membrane complexes, dense organelles that resemble “rhoptries” and apparent nuclear division. Together these results suggest that [Na+]i disruptor drugs by altering levels of cholesterol in the parasite, dysregulate trophozoite to schizont development and cause parasite demise.

Highlights

  • Billions of people living in regions endemic for malaria are confronted with the looming threat of Plasmodium falciparum parasites resistant to currently effective artemisinin combination therapies [1]

  • There are new antimalarial drugs under development, and among these are 3 clinical candidate drugs that have the propensity to cause sodium leakage into parasites growing inside human red blood cells

  • Our findings suggest that the drug-treated parasite rapidly acquires cholesterol and clusters containing lipid-embedded proteins merozoite surface protein-1 (MSP1) and MSP2 form within the plasma membrane

Read more

Summary

Introduction

Billions of people living in regions endemic for malaria are confronted with the looming threat of Plasmodium falciparum parasites resistant to currently effective artemisinin combination therapies [1]. The existence of resistance-associated mutations in PfATP4 has been interpreted as indicating that the large number of chemical classes causing Na+ influx into isolated trophozoites are all direct inhibitors of PfATP4, and that it is the inhibition of the Na+ efflux function of PfATP4 that leads to the rapid increase in [Na+]i. While this appears to be a reasonable interpretation, there is no direct evidence at this time to show that PfATP4 is a Na+ pump, or that various antimalarials doi:10.1371/journal.ppat.1005647.g001 causing [Na+]i disruption directly inhibit its Na+ pumping activity. It appears possible that Na+ homeostasis within the intraerythrocytic stages of P. falciparum might be regulated by a complex network, and that perturbation of this network by a variety of small molecules could lead to Na+ homeostasis disruption

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call